World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
19941
World Ranking
3462
National Ranking
1606

Overview

David Wofsy is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on medicine, with a significant emphasis on immunology and microbiology. Within these fields, the subfields of rheumatology and immunology comprise the largest shares of their work, further extending into nephrology, hepatology, and artificial intelligence.

The main topics addressed in their scholarly activities include systemic lupus erythematosus research, atherosclerosis and cardiovascular diseases, renal diseases and glomerulopathies, liver diseases and immunity, T-cell and B-cell immunology, seismology and earthquake studies, and immune cells in cancer.

Several recent papers highlight their contributions to the understanding of lupus nephritis and systemic lupus erythematosus. These include:

  • Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (2020, Arthritis & Rheumatology)
  • Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis (2020, JCI Insight)
  • Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis (2021, Arthritis & Rheumatology)
  • European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021, Annals of the Rheumatic Diseases)
  • Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020, Annals of the Rheumatic Diseases)

Frequent coauthors associated with David Wofsy include Betty Diamond, Peter Izmirly, Jill P. Buyon, Diane L. Kamen, and Andrea Fava.

Wofsy has published extensively in several prominent venues, including:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Arthritis & Rheumatology
  • Annals of the Rheumatic Diseases
  • Lara D. Veeken
  • UNC Libraries

Best Publications

  • 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Martin Aringer;Karen Costenbader;David Daikh;Ralph Brinks

  • Treatment of murine lupus with CTLA4Ig.

    Barbara K. Finck;Peter S. Linsley;David Wofsy

  • The immune cell landscape in kidneys of patients with lupus nephritis

    Arnon Arazi;Deepak A Rao;Celine C Berthier;Anne Davidson

  • Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

    D Wofsy;W E Seaman

  • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

    Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

  • Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

    David Isenberg;Gerald B. Appel;Gabriel Contreras;Mary A. Dooley

  • INTERLEUKIN 6 PROMOTES MURINE LUPUS IN NZB/NZW F1 MICE

    B K Finck;B Chan;D Wofsy

  • Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells.

    J A Ledbetter;P J Martin;C E Spooner;D Wofsy

  • Treatment of Lupus Nephritis with Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

    Anca Askanase;Margie Byron;Lynette Keyes-Elstein

  • Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

    David Isenberg;Caroline Gordon;Daiana Licu;Samuel Copt

  • Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.

    D Wofsy;W E Seaman

  • Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.

    D Wofsy;E D Murphy;J B Roths;M J Dauphinée

  • PD-1hiCXCR5– T peripheral helper cells promote B cell responses in lupus via MAF and IL-21

    Alexandra V. Bocharnikov;Joshua Keegan;Vanessa S. Wacleche;Ye Cao

  • Treatment of murine lupus with monoclonal anti-T cell antibody.

    D Wofsy;J A Ledbetter;P L Hendler;W E Seaman

  • Interleukin 2 deficiency is a common feature of autoimmune mice.

    M J Dauphinée;S B Kipper;D Wofsy;N Talal

  • Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.

    David I. Daikh;Barbara K. Finck;Barbara K. Finck;Peter S. Linsley;Diane Hollenbaugh

  • Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice

    Caroline Gordon;Caroline Gordon;Gerald E. Ranges;John S. Greenspan;David Wofsy;David Wofsy

  • Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide

    David I. Daikh;David Wofsy

  • Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

    John C. Davis;Mark C. Totoritis;J. A. Y. Rosenberg;Thomas A. Sklenar

  • Induction of immune tolerance by administration of monoclonal antibody to L3T4.

    N L Gutstein;W E Seaman;J H Scott;D Wofsy

Frequent Co-Authors

Betty Diamond
Betty Diamond Feinstein Institute for Medical Research
David Jayne
David Jayne University of Cambridge
Caroline Gordon
Caroline Gordon University of Birmingham
Karen H. Costenbader
Karen H. Costenbader Brigham and Women's Hospital
William E. Seaman
William E. Seaman University of California, San Francisco
Dimitrios T. Boumpas
Dimitrios T. Boumpas National and Kapodistrian University of Athens
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Anne Davidson
Anne Davidson Feinstein Institute for Medical Research
Nir Hacohen
Nir Hacohen Harvard University
David A. Hildeman
David A. Hildeman Cincinnati Children's Hospital Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related online degrees can open diverse career pathways in healthcare and research. Transitioning from a Family Nurse Practitioner to a more specialized role often requires targeted education, such as an fnp to acute care certification, which equips nurses to handle complex clinical situations in acute settings.

Accelerated programs are popular among professionals seeking faster entry into advanced practice roles. Many choose a nurse practitioner accelerated program for its focused curriculum and flexibility, allowing them to gain advanced clinical skills alongside immunology expertise.

For those without a nursing background, the best online option is often a Bachelor of Science in Nursing (BSN). Resources highlighting the best online bsn programs for non nurses make it easier to find accessible, high-quality programs that pave the way to immunology-related nursing careers.

Additionally, if you're looking for quicker access into nursing, researching the easiest accelerated nursing programs can help identify pathways that fit your schedule and academic profile, facilitating a smooth transition into the healthcare field with a focus on immunology.

Best Scientists Citing David Wofsy

Trending Scientists

Recently Published Articles